These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 27579542)

  • 21. Lactate levels and risk of lactic acidosis with metformin in diabetic kidney disease patients.
    Bipi PK; George J; Gomathy S; Gracious N; Kumar S; Mohandas MK
    Saudi J Kidney Dis Transpl; 2017; 28(6):1356-1361. PubMed ID: 29265047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluating the potential benefits of metformin in patients with cardiovascular disease and heart failure.
    Norwood DK; Chilipko AA; Amin SM; Macharia D; Still KL
    Consult Pharm; 2013 Sep; 28(9):579-83. PubMed ID: 24007890
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safe Use of Metformin in Adults With Type 2 Diabetes and Chronic Kidney Disease: Lower Dosages and Sick-Day Education Are Essential.
    MacCallum L; Senior PA
    Can J Diabetes; 2019 Feb; 43(1):76-80. PubMed ID: 30061044
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic Effects of Metformin in the Failing Heart.
    Dziubak A; Wójcicka G; Wojtak A; Bełtowski J
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30248910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.
    Toyama T; Neuen BL; Jun M; Ohkuma T; Neal B; Jardine MJ; Heerspink HL; Wong MG; Ninomiya T; Wada T; Perkovic V
    Diabetes Obes Metab; 2019 May; 21(5):1237-1250. PubMed ID: 30697905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute effects of fructose consumption on uric acid and plasma lipids in patients with impaired renal function.
    Zawiasa A; Nowicki M
    Metabolism; 2013 Oct; 62(10):1462-9. PubMed ID: 23866980
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review.
    Wulffelé MG; Kooy A; de Zeeuw D; Stehouwer CD; Gansevoort RT
    J Intern Med; 2004 Jul; 256(1):1-14. PubMed ID: 15189360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metformin in patients with chronic kidney disease: strengths and weaknesses.
    Rocha A; Almeida M; Santos J; Carvalho A
    J Nephrol; 2013; 26(1):55-60. PubMed ID: 22641582
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study.
    Solini A; Penno G; Bonora E; Fondelli C; Orsi E; Trevisan R; Vedovato M; Cavalot F; Cignarelli M; Morano S; Ferrannini E; Pugliese G;
    J Am Geriatr Soc; 2013 Aug; 61(8):1253-61. PubMed ID: 23889588
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The influence of metformin and the presence of type 2 diabetes mellitus on mortality and hospitalisation in patients with heart failure.
    Retwiński A; Kosmalski M; Crespo-Leiro M; Maggioni A; Opolski G; Ponikowski P; Poloński L; Jankowska E; Drzewoski J; Drożdż J
    Kardiol Pol; 2018; 76(9):1336-1343. PubMed ID: 29862487
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metformin: A Candidate Drug for Renal Diseases.
    Corremans R; Vervaet BA; D'Haese PC; Neven E; Verhulst A
    Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30583483
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Phantom of Metformin-Induced Lactic Acidosis in End-Stage Renal Disease Patients: Time to Reconsider with Peritoneal Dialysis Treatment.
    Al-Hwiesh AK; Abdul-Rahman IS; Noor AS; Nasr-El-Deen MA; Abdelrahman A; El-Salamoni TS; Al-Muhanna FA; Al-Otaibi K; Al-Audah N
    Perit Dial Int; 2017 1-2; 37(1):56-62. PubMed ID: 27680758
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Type 2 diabetes treatment and progression of chronic kidney disease in Italian family practice.
    Ermini G; Tosetti C; Zocchi D; Mandreoli M; Caletti MT; Marchesini G;
    J Endocrinol Invest; 2019 Jul; 42(7):787-796. PubMed ID: 30465248
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients.
    Eurich DT; Weir DL; Majumdar SR; Tsuyuki RT; Johnson JA; Tjosvold L; Vanderloo SE; McAlister FA
    Circ Heart Fail; 2013 May; 6(3):395-402. PubMed ID: 23508758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of Metformin in Heart Failure: From Pathophysiological Rationale to Clinical Evidence.
    Salvatore T; Galiero R; Caturano A; Vetrano E; Rinaldi L; Coviello F; Di Martino A; Albanese G; Marfella R; Sardu C; Sasso FC
    Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944478
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanism of glucose-lowering by metformin in type 2 diabetes: Role of bile acids.
    Sansome DJ; Xie C; Veedfald S; Horowitz M; Rayner CK; Wu T
    Diabetes Obes Metab; 2020 Feb; 22(2):141-148. PubMed ID: 31468642
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Should Restrictions Be Relaxed for Metformin Use in Chronic Kidney Disease? Yes, They Should Be Relaxed! What's the Fuss?
    Bakris GL; Molitch ME
    Diabetes Care; 2016 Jul; 39(7):1287-91. PubMed ID: 27330130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.